Skip to main content
. 2024 Jan 10;23(4):476–487. doi: 10.2174/1871527322666230331121028

Fig. (2).

Fig. (2)

Comparison of tavapadon and levodopa on motor activity in an MPTP-model of PD in nonhuman primates. Higher doses of tavapadon (0.1 and 0.15 mg/kg) led to an improved duration of efficacy versus levodopa. MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD, Parkinson’s disease. Adapted with permission from Young D, Popiolek M, Trapa P, et al. ACS Chem Neurosci 2020; 11(4): 560-6 [33]. ©Copyright 2020 American Chemical Society.